{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:59:58Z","timestamp":1790618398241,"version":"4.1.0"},"reference-count":209,"publisher":"Springer Science and Business Media LLC","issue":"S8","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Eine Immunsuppression unterschiedlicher Genese geht mit einem erh\u00f6hten Risiko diverser Infektionen einher. Die Impfpr\u00e4vention besitzt daher bei immunsupprimierten Patientinnen und Patienten einen hohen Stellenwert.<\/jats:p>\n                  <jats:p>Auf Grundlage der verf\u00fcgbaren Evidenz sowie immunologischer und theoretischer \u00dcberlegungen wurden 2016 erstmals Empfehlungen zur Impfversorgung immunsupprimierter Personen formuliert. Diese Empfehlungen wurden nun umfassend aktualisiert und erweitert. Ziel ist die Bereitstellung einer praxisorientierten, indikations- und therapiebezogenen Handlungsanleitung f\u00fcr die klinische Versorgung. Eine Anleitung f\u00fcr die vorliegenden Impfempfehlungen, die gleichzeitig als Entscheidungsbaum f\u00fcr das praktische Vorgehen dienen kann, erleichtert die Orientierung.<\/jats:p>\n                  <jats:p>Die vorliegenden Empfehlungen umfassen einen einf\u00fchrenden Abschnitt zu grundlegenden Aspekten der Immunsuppression sowie zu praxisrelevanten immunologischen und organisatorischen Fragestellungen im Zusammenhang mit Impfplanung, Ermittlung der Impff\u00e4higkeit und \u00dcberpr\u00fcfung des Impferfolgs. Dar\u00fcber hinaus werden aktuelle Entwicklungen zu relevanten Impfstoffen ber\u00fccksichtigt.<\/jats:p>\n                  <jats:p>Im weiteren Verlauf erfolgt eine systematische Darstellung der in verschiedenen medizinischen Fachgebieten h\u00e4ufig eingesetzten immunsuppressiven Wirkstoffe. Diese werden hinsichtlich ihres Immunsuppressionsgrades und der damit verbundenen Infektionsrisiken eingeordnet. Erg\u00e4nzend werden standardisierte Impfschemata bereitgestellt, die den jeweiligen Wirkstoffklassen zugeordnet sind und eine strukturierte Orientierung im klinischen Alltag erm\u00f6glichen. Die Evaluierung der Impff\u00e4higkeit kann immer nur im Zusammenspiel zwischen Grunderkrankung und geplanter oder bestehender Therapie getroffen werden.<\/jats:p>\n                  <jats:p>Besonderen klinischen Situationen \u2013\u00a0einschlie\u00dflich jenen, in denen Impfungen nicht durchgef\u00fchrt werden k\u00f6nnen sowie Reiseimpfungen im Kontext der Immunsuppression\u00a0\u2013 sind eigene Kapitel gewidmet. Zur Sicherstellung der l\u00e4ngerfristigen Aktualit\u00e4t wird an geeigneten Stellen auf aktualisierte externe Quellen verwiesen, die gesammelt am Ende des Dokuments aufgelistet sind.<\/jats:p>\n                  <jats:p>Dieses Dokument ist eine allgemeine Empfehlung, ohne Anspruch auf Vollst\u00e4ndigkeit. Das spezifische Vorgehen in der klinischen Praxis kann an die Gegebenheiten in den einzelnen Fachgebieten angepasst werden und es wird auf die jeweiligen Fachgesellschaften verwiesen.<\/jats:p>","DOI":"10.1007\/s00508-026-02754-4","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T12:20:57Z","timestamp":1783081257000},"page":"641-712","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impfungen bei Immunsuppression, Immundefekten und immunmodulierenden Therapien: Empfehlungen\u00a0\u2013 Update 2026","Vaccination of immunocompromised individuals: Expert opinion \u2013 update 2026"],"prefix":"10.1007","volume":"138","author":[{"given":"Ursula","family":"Wiedermann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Bartuschka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Sophie","family":"Berghoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Donschacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Eser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"F\u00f6rster-Waldl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"G\u00f6schl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Grabmeier-Pfistershammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Keil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"K\u00f6nig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Koppelst\u00e4tter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Kornek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfried F.","family":"Pickl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Scheinecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Waas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Wisgrill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"ISP-Arbeitsgruppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Wiedermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"G\u00f6schl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Scheinecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Grabmeier-Pfistershammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Eser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Kornek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Sophie","family":"Berghoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Donschacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Keil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"F\u00f6rster-Waldl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Wisgrill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfried F.","family":"Pickl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Bartuschka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Waas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Bartuschka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Wessely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Koppelst\u00e4tter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Wiedermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Duftner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"K\u00f6nig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Burgmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Tucek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Philadelphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"K\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidemarie","family":"Holzmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"issue":"4","key":"2754_CR1","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.dmih2-0026-2016","volume":"4","author":"LK Dropulic","year":"2016","unstructured":"Dropulic LK, Lederman HM. Overview of infections in the immunocompromised host. Microbiology Spectrum. 2016;4(4)DMIH2-0026-2016. https:\/\/doi.org\/10.1128\/microbiolspec.dmih2-0026-2016.","journal-title":"Microbiology Spectrum"},{"issue":"4","key":"2754_CR2","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00508-016-1033-6","volume":"128","author":"U Wiedermann","year":"2016","unstructured":"Wiedermann U, Sitte HH, Burgmann H, Eser A, Falb P, Holzmann H, et al. Impfungen bei Immundefekten\/Immunsuppression \u2013 Expertenstatement und Empfehlungen. Wien Klin Wochensch. 2016;128(4):337\u201376. https:\/\/doi.org\/10.1007\/s00508-016-1033-6.","journal-title":"Wien Klin Wochensch"},{"issue":"10","key":"2754_CR3","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.3390\/vaccines10101654","volume":"10","author":"S Shapiro Ben David","year":"2022","unstructured":"Shapiro Ben David S, Goren I, Mourad V, Cahan A. Vaccination coverage among immunocompromised patients in a large health maintenance organization: Findings from a novel computerized registry. Vaccines. 2022;10(10):1654\u20131654. https:\/\/doi.org\/10.3390\/vaccines10101654.","journal-title":"Vaccines"},{"issue":"12","key":"2754_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12121383","volume":"12","author":"E te Linde","year":"2024","unstructured":"te Linde E, Hensgens MPM, Vollaard AM, Verbon A, Bruns AHW. Vaccination coverage for medically indicated vaccines in a\u00a0convenience sample of severely immunocompromised patients with COVID-19: An observational cohort study. Vaccines. 2024;12(12)1383.","journal-title":"Vaccines"},{"issue":"6","key":"2754_CR5","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1007\/s00103-017-2555-4","volume":"60","author":"T Niehues","year":"2017","unstructured":"Niehues T, Bogdan C, Hecht J, Mertens T, Wiese-Posselt M, Zepp F. Impfen bei Immundefizienz. Bundesgesundheitsbl. 2017;60(6):674\u201384. https:\/\/doi.org\/10.1007\/s00103-017-2555-4.","journal-title":"Bundesgesundheitsbl"},{"key":"2754_CR6","unstructured":"Bundesministerium f\u00fcr Soziales G, Pflege und Konsumentenschutz, Nationales Impfgremium. \u00d6stereichischer Impfplan 2025\/2026, Version 1.1. 2025. https:\/\/www.sozialministerium.gv.at\/Themen\/Gesundheit\/Impfen\/impfplan.html. Zugegriffen: 2. M\u00e4rz 2026."},{"issue":"12","key":"2754_CR7","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1007\/s00467-023-05969-z","volume":"38","author":"K Kamei","year":"2023","unstructured":"Kamei K. Live attenuated vaccines in patients receiving immunosuppressive agents. Pediatr Nephrol. 2023;38(12):3889\u2013900. https:\/\/doi.org\/10.1007\/s00467-023-05969-z.","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"2754_CR8","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/acr.25045","volume":"75","author":"AR Bass","year":"2023","unstructured":"Bass AR, Chakravarty E, Akl EA, Bingham CO, Calabrese L, Cappelli LC, et al. 2022 American College of Rheumatology guideline for vaccinations in patients with rheumatic and musculoskeletal diseases. Arthritis Care Res (Hoboken). 2023;75(3):449\u201364. https:\/\/doi.org\/10.1002\/acr.25045.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2754_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.25646\/12971.4","volume":"4","author":"St\u00e4ndige Impfkommission beim Robert-Koch-Institut","year":"2025","unstructured":"St\u00e4ndige Impfkommission beim Robert-Koch-Institut. Empfehlungen der St\u00e4ndigen Impfkommission beim Robert Koch-Institut 2025. Epid Bull. 2025;4:1\u201375. https:\/\/doi.org\/10.25646\/12971.4.","journal-title":"Epid Bull"},{"issue":"6","key":"2754_CR10","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.it.2020.04.001","volume":"41","author":"JS Tsang","year":"2020","unstructured":"Tsang JS, Doba\u00f1o C, VanDamme P, Moncunill G, Marchant A, Othman RB, et al. Improving vaccine-induced immunity: can baseline predict outcome? Trends Immunol. 2020;41(6):457\u201365. https:\/\/doi.org\/10.1016\/j.it.2020.04.001.","journal-title":"Trends Immunol"},{"issue":"2","key":"2754_CR11","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","volume":"21","author":"AJ Pollard","year":"2021","unstructured":"Pollard AJ, Bijker EM. A guide to vaccinology: from basic principles to new developments. Nat Rev Immun. 2021;21(2):83\u2013100. https:\/\/doi.org\/10.1038\/s41577-020-00479-7.","journal-title":"Nat Rev Immun"},{"key":"2754_CR12","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000788","author":"AL Desage","year":"2021","unstructured":"Desage AL, Bouleftour W, Rivoirard R, Magne N, Collard O, Fournel P, et al. Vaccination and immune checkpoint inhibitors: Does vaccination increase the risk of immune-related adverse events? A systematic review of literature. Am J Clin Oncol. 2021; https:\/\/doi.org\/10.1097\/COC.0000000000000788.","journal-title":"Am J Clin Oncol"},{"key":"2754_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12111270","author":"J New","year":"2024","unstructured":"New J, Shenton L, Ksayer R, Wang J, Zakharia K, Nicholson LJ, et al. Immune checkpoint inhibitors and vaccination: Assessing safety, efficacy, and synergistic potential. Vaccines (Basel). 2024; https:\/\/doi.org\/10.3390\/vaccines12111270.","journal-title":"Vaccines (Basel)"},{"issue":"8089","key":"2754_CR14","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/s41586-025-09655-y","volume":"647","author":"AJ Grippin","year":"2025","unstructured":"Grippin AJ, Marconi C, Copling S, Li N, Braun C, Woody C, et al. SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade. Nature. 2025;647(8089):488\u201397. https:\/\/doi.org\/10.1038\/s41586-025-09655-y.","journal-title":"Nature"},{"issue":"7","key":"2754_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13604","volume":"51","author":"F Spagnolo","year":"2021","unstructured":"Spagnolo F, Boutros A, Croce E, Cecchi F, Arecco L, Tanda E, et al. Influenza vaccination in cancer patients receiving immune checkpoint inhibitors: A systematic review. Eur J Clin Invest. 2021;51(7)e13604. https:\/\/doi.org\/10.1111\/eci.13604.","journal-title":"Eur J Clin Invest"},{"issue":"8","key":"2754_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10081195","volume":"10","author":"MA Lopez-Olivo","year":"2022","unstructured":"Lopez-Olivo MA, Valerio V, Karpes Matusevich AR, Brizio M, Kwok M, Geng Y, et al. Safety and efficacy of influenza vaccination in patients receiving immune checkpoint inhibitors. Systematic review with meta-analysis. Vaccines. 2022;10(8)1195. https:\/\/doi.org\/10.3390\/vaccines10081195.","journal-title":"Vaccines"},{"issue":"2","key":"2754_CR17","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1080\/07853890.2017.1407035","volume":"50","author":"V Vetter","year":"2018","unstructured":"Vetter V, G\u00fclhan D, R FL, Jyothsna K, Shapiro M. Understanding modern-day vaccines: what you need to know. Ann Med. 2018;50(2):110\u201320. https:\/\/doi.org\/10.1080\/07853890.2017.1407035.","journal-title":"Ann Med"},{"issue":"3","key":"2754_CR18","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/s1045-1056(05)80040-5","volume":"20","author":"JS Robertson","year":"1992","unstructured":"Robertson JS, Nicolson C, Newman R, Major D, Dunleavy U, Wood JM. High growth reassortant influenza vaccine viruses: new approaches to their control. Biologicals. 1992;20(3):213\u201320. https:\/\/doi.org\/10.1016\/s1045-1056(05)80040-5.","journal-title":"Biologicals"},{"issue":"Suppl 1","key":"2754_CR19","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1093\/infdis\/174.supplement_1.s73","volume":"174","author":"HF Clark","year":"1996","unstructured":"Clark HF, Offit PA, Ellis RW, Eiden JJ, Krah D, Shaw AR, et al. The development of multivalent bovine rotavirus (strain WC 3) reassortant vaccine for infants. J\u00a0Infect Dis. 1996;174(Suppl 1):S73\u2013S80. https:\/\/doi.org\/10.1093\/infdis\/174.supplement_1.s73.","journal-title":"J Infect Dis"},{"issue":"11","key":"2754_CR20","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","volume":"20","author":"N Chaudhary","year":"2021","unstructured":"Chaudhary N, Weissman D, Whitehead KA. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat Rev Drug Discov. 2021;20(11):817\u201338. https:\/\/doi.org\/10.1038\/s41573-021-00283-5.","journal-title":"Nat Rev Drug Discov"},{"key":"2754_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.nantod.2019.100766","volume":"28","author":"R Verbeke","year":"2019","unstructured":"Verbeke R, Lentacker I, De Smedt SC, Dewitte H. Three decades of messenger RNA vaccine development. Nano Today. 2019;28:100766. https:\/\/doi.org\/10.1016\/j.nantod.2019.100766.","journal-title":"Nano Today"},{"issue":"3","key":"2754_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032700","volume":"24","author":"V Gote","year":"2023","unstructured":"Gote V, Bolla PK, Kommineni N, Butreddy A, Nukala PK, Palakurthi SS, et al. A comprehensive review of mRNA vaccines. Int J Molec Sci. 2023;24(3)2700.","journal-title":"Int J Molec Sci"},{"issue":"3","key":"2754_CR23","doi-asserted-by":"publisher","first-page":"608","DOI":"10.3390\/covid1030051","volume":"1","author":"AW Currier","year":"2021","unstructured":"Currier AW, Jeshurin MC, Sampson VB. SARS-CoV-2 targets and COVID-19 vaccines. COVID. 2021;1(3):608\u201321.","journal-title":"COVID"},{"issue":"3","key":"2754_CR24","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s40259-023-00585-7","volume":"37","author":"M Arjomandnejad","year":"2023","unstructured":"Arjomandnejad M, Dasgupta I, Flotte TR, Keeler AM. Immunogenicity of recombinant adeno-associated virus (AAV) vectors for gene transfer. BioDrugs. 2023;37(3):311\u201329. https:\/\/doi.org\/10.1007\/s40259-023-00585-7.","journal-title":"BioDrugs"},{"issue":"3685","key":"2754_CR25","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1126\/science.149.3685.754","volume":"149","author":"RW Atchison","year":"1965","unstructured":"Atchison RW, Casto BC, Hammon WM. Adenovirus-associated defective virus particles. Science. 1965;149(3685):754\u20136. https:\/\/doi.org\/10.1126\/science.149.3685.754.","journal-title":"Science"},{"issue":"8","key":"2754_CR26","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/s41563-020-0746-0","volume":"19","author":"D van Riel","year":"2020","unstructured":"van Riel D, de Wit E. Next-generation vaccine platforms for COVID-19. Nat Mater. 2020;19(8):810\u20132. https:\/\/doi.org\/10.1038\/s41563-020-0746-0.","journal-title":"Nat Mater"},{"key":"2754_CR27","doi-asserted-by":"publisher","unstructured":"Yong\u00a0SJ, Kenny\u00a0T-A, Halim\u00a0A, Munipalli\u00a0B, Alhashem\u00a0YN, AlSaihati\u00a0H, et\u00a0al. Post-COVID-19 vaccination (or Long Vax) syndrome: Putative manifestation, pathophysiology, and therapeutic options. Rev Med Virol. 2025;35(5):e70070. https:\/\/doi.org\/10.1002\/rmv.70070.","DOI":"10.1002\/rmv.70070"},{"key":"2754_CR28","unstructured":"European Medicines Agency. Vaxzevria (previously COVID-19 Vaccine AstraZeneca). 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vaxzevria#overview. Zugegriffen: 26. M\u00e4rz 2025."},{"key":"2754_CR29","unstructured":"European Medicines Agency. EPAR Jcovden (COVID-19 Vaccine Janssen). 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/jcovden. Zugegriffen: 13. Jan. 2025."},{"issue":"1","key":"2754_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01557-7","volume":"8","author":"T Zhao","year":"2023","unstructured":"Zhao T, Cai Y, Jiang Y, He X, Wei Y, Yu Y, et al. Vaccine adjuvants: mechanisms and platforms. Signal Transduct Target Ther. 2023;8(1)283. https:\/\/doi.org\/10.1038\/s41392-023-01557-7.","journal-title":"Signal Transduct Target Ther"},{"issue":"5566","key":"2754_CR31","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.1071059","volume":"296","author":"P Matzinger","year":"2002","unstructured":"Matzinger P. The danger model: A\u00a0renewed sense of self. Science. 2002;296(5566):301\u20135. https:\/\/doi.org\/10.1126\/science.1071059.","journal-title":"Science"},{"issue":"4","key":"2754_CR32","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1007\/s00103-019-02921-1","volume":"62","author":"R Wagner","year":"2019","unstructured":"Wagner R, Hildt E. Zusammensetzung und Wirkmechanismen von Adjuvanzien in zugelassenen viralen Impfstoffen. Bundesgesundheitsbl. 2019;62(4):462\u201371. https:\/\/doi.org\/10.1007\/s00103-019-02921-1.","journal-title":"Bundesgesundheitsbl"},{"issue":"4","key":"2754_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/btm2.10663","volume":"9","author":"M Goetz","year":"2024","unstructured":"Goetz M, Thotathil N, Zhao Z, Mitragotri S. Vaccine adjuvants for infectious disease in the clinic. Bioeng Translat Med. 2024;9(4)e10663. https:\/\/doi.org\/10.1002\/btm2.10663.","journal-title":"Bioeng Translat Med"},{"key":"2754_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9020147","author":"E Bettini","year":"2021","unstructured":"Bettini E, Locci M. SARS-CoV-2 mRNA vaccines: Immunological mechanism and beyond. Vaccines (Basel). 2021; https:\/\/doi.org\/10.3390\/vaccines9020147.","journal-title":"Vaccines (Basel)"},{"key":"2754_CR35","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.coi.2021.07.003","volume":"71","author":"D Ndwandwe","year":"2021","unstructured":"Ndwandwe D, Wiysonge CS. COVID-19 vaccines. Curr Opin Immunol. 2021;71:111\u20136. https:\/\/doi.org\/10.1016\/j.coi.2021.07.003.","journal-title":"Curr Opin Immunol"},{"key":"2754_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2020.101430","volume":"50","author":"E Sasso","year":"2020","unstructured":"Sasso E, D\u2019Alise AM, Zambrano N, Scarselli E, Folgori A, Nicosia A. New viral vectors for infectious diseases and cancer. Semin Immunol. 2020;50:101430. https:\/\/doi.org\/10.1016\/j.smim.2020.101430.","journal-title":"Semin Immunol"},{"issue":"5","key":"2754_CR37","doi-asserted-by":"publisher","first-page":"e278","DOI":"10.1016\/S1473-3099(24)00150-6","volume":"24","author":"DY Lin","year":"2024","unstructured":"Lin DY, Huang S, Milinovich A, Duggal A, Wang X. Effectiveness of XBB.1.5 vaccines and antiviral drugs against severe outcomes of omicron infection in the USA. Lancet Infect Dis. 2024;24(5):e278\u2013e80. https:\/\/doi.org\/10.1016\/S1473-3099(24)00150-6.","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"2754_CR38","doi-asserted-by":"publisher","first-page":"271","DOI":"10.15585\/mmwr.mm7312a5","volume":"73","author":"R Link-Gelles","year":"2024","unstructured":"Link-Gelles R, Rowley EAK, DeSilva MB, Dascomb K, Irving SA, Klein NP, et al. Interim effectiveness of updated 2023-2024 (monovalent XBB.1.5) COVID-19 vaccines against COVID-19-associated hospitalization among adults aged \u2265\u202f18\u00a0years with immunocompromising conditions - VISION Network, September 2023-February 2024. MMWR Morb Mortal Wkly Rep. 2024;73(12):271\u20136. https:\/\/doi.org\/10.15585\/mmwr.mm7312a5.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"2754_CR39","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.chom.2024.01.014","volume":"32","author":"Q Wang","year":"2024","unstructured":"Wang Q, Guo Y, Bowen A, Mellis IA, Valdez R, Gherasim C, et al. XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1. Cell Host Microbe. 2024;32(3):315\u2013321.e3. https:\/\/doi.org\/10.1016\/j.chom.2024.01.014.","journal-title":"Cell Host Microbe"},{"key":"2754_CR40","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.Es.2024.29.1.2300703","author":"CH van Werkhoven","year":"2024","unstructured":"van Werkhoven CH, Valk AW, Smagge B, de Melker HE, Knol MJ, Hahn\u00e9 SJ, et al. Early COVID-19 vaccine effectiveness of XBB.1.5 vaccine against hospitalisation and admission to intensive care, the Netherlands, 9 October to 5 December 2023. Euro Surveill. 2024; https:\/\/doi.org\/10.2807\/1560-7917.Es.2024.29.1.2300703.","journal-title":"Euro Surveill"},{"issue":"22","key":"2754_CR41","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1056\/NEJMc2402779","volume":"390","author":"DY Lin","year":"2024","unstructured":"Lin DY, Du Y, Xu Y, Paritala S, Donahue M, Maloney P. Durability of XBB.1.5 vaccines against omicron subvariants. N\u00a0Engl J Med. 2024;390(22):2124\u20137. https:\/\/doi.org\/10.1056\/NEJMc2402779.","journal-title":"N Engl J Med"},{"key":"2754_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.889138","volume":"13","author":"A Wagner","year":"2022","unstructured":"Wagner A, Garner-Spitzer E, Sch\u00f6tta A-M, Orola M, Wessely A, Zwazl I, et al. SARS-CoV-2-mRNA booster vaccination reverses non-responsiveness and early antibody waning in immunocompromised patients \u2013 A phase four study comparing immune responses in patients with solid cancers, multiple myeloma and inflammatory bowel disease. Front Immunol. 2022;13:889138. https:\/\/doi.org\/10.3389\/fimmu.2022.889138.","journal-title":"Front Immunol"},{"key":"2754_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104788","volume":"96","author":"E Garner-Spitzer","year":"2023","unstructured":"Garner-Spitzer E, Wagner A, Gudipati V, Schoetta AM, Orola-Taus M, Kundi M, et al. Lower magnitude and faster waning of antibody responses to SARS-CoV-2 vaccination in anti-TNF-\u03b1-treated IBD patients are linked to lack of activation and expansion of cTfh1 cells and impaired B memory cell formation. EBioMedicine. 2023;96:104788. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104788.","journal-title":"EBioMedicine"},{"issue":"1","key":"2754_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33036-y","volume":"13","author":"D Mrak","year":"2022","unstructured":"Mrak D, Sieghart D, Simader E, Tobudic S, Radner H, Mandl P, et al. Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trial. Nat Commun. 2022;13(1)5362. https:\/\/doi.org\/10.1038\/s41467-022-33036-y.","journal-title":"Nat Commun"},{"key":"2754_CR45","unstructured":"European Medicines Agency. EPAR Synagis. 2023. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/synagis. Zugegriffen: 13. Jan. 2025."},{"key":"2754_CR46","unstructured":"European Medicines Agency. EPAR Beyfortus. 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/beyfortus. Zugegriffen: 13. Jan. 2025."},{"key":"2754_CR47","unstructured":"European Medicines Agency. EPAR Enflonsia. 2026. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/enflonsia. Zugegriffen: 29. Jun. 2026."},{"key":"2754_CR48","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad513","author":"A Njue","year":"2023","unstructured":"Njue A, Nuabor W, Lyall M, Margulis A, Mauskopf J, Curcio D, et al. Systematic literature review of risk factors for poor outcomes among adults with respiratory syncytial virus infection in high-income countries. Open Forum Infect Dis. 2023; https:\/\/doi.org\/10.1093\/ofid\/ofad513.","journal-title":"Open Forum Infect Dis"},{"key":"2754_CR49","unstructured":"European Medicines Agency: EPAR Arexvy. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/arexvy (2026). Zugegriffen: 24. Mai 2026."},{"key":"2754_CR50","unstructured":"European Medicines Agency: EPAR Abrysvo. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/abrysvo (2026). Zugegriffen: 24. Mai 2026."},{"key":"2754_CR51","unstructured":"European Medicines Agency: EPAR mResvia. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mresvia (2026). Zugegriffen: 24. Mai 2026."},{"issue":"6","key":"2754_CR52","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/j.ymthe.2018.03.010","volume":"26","author":"S Sabnis","year":"2018","unstructured":"Sabnis S, Kumarasinghe ES, Salerno T, Mihai C, Ketova T, Senn JJ, et al. A novel amino lipid series for mRNA delivery: Improved endosomal escape and sustained pharmacology and safety in non-human primates. Mol Ther. 2018;26(6):1509\u201319. https:\/\/doi.org\/10.1016\/j.ymthe.2018.03.010.","journal-title":"Mol Ther"},{"key":"2754_CR53","unstructured":"European Medicines Agency. Assessment report: COVID-19 Vaccine Moderna. 2021. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/spikevax-previously-covid-19-vaccine-moderna-epar-public-assessment-report_en.pdf. Zugegriffen: 27. M\u00e4rz 2025."},{"key":"2754_CR54","unstructured":"ClinicalTrials.gov. A study on the immune response and safety of vaccine against respiratory syncytial virus (RSV) given to adults 18 to 49 years of age at increased risk for respiratory syncytial virus disease, compared to older adults 60 years of age and above. 2025. https:\/\/clinicaltrials.gov\/study\/NCT06389487?tab=results. Zugegriffen: 23. Dez. 2025."},{"key":"2754_CR55","unstructured":"European Medicines Agency. EPAR Shingrix. 2023. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/shingrix. Zugegriffen: 13. Jan. 2025."},{"issue":"10","key":"2754_CR56","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac485","volume":"9","author":"A Strezova","year":"2022","unstructured":"Strezova A, Diez-Domingo J, Al Shawafi K, Tinoco JC, Shi M, Pirrotta P, et al. Long-term protection against herpes zoster by the adjuvanted recombinant zoster vaccine: Interim efficacy, immunogenicity, and safety results up to 10 years after initial vaccination. Open Forum Infect Dis. 2022;9(10)ofac485. https:\/\/doi.org\/10.1093\/ofid\/ofac485.","journal-title":"Open Forum Infect Dis"},{"issue":"9","key":"2754_CR57","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/s1473-3099(19)30163-x","volume":"19","author":"AF Dagnew","year":"2019","unstructured":"Dagnew AF, Ilhan O, Lee WS, Woszczyk D, Kwak JY, Bowcock S, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. Lancet Infect Dis. 2019;19(9):988\u20131000. https:\/\/doi.org\/10.1016\/s1473-3099(19)30163-x.","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"2754_CR58","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1001\/jama.2019.9053","volume":"322","author":"A Bastidas","year":"2019","unstructured":"Bastidas A, de la Serna J, El Idrissi M, Oostvogels L, Quittet P, L\u00f3pez-Jim\u00e9nez J, et al. Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: A randomized clinical trial. JAMA. 2019;322(2):123\u201333. https:\/\/doi.org\/10.1001\/jama.2019.9053.","journal-title":"JAMA"},{"key":"2754_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103241","volume":"83","author":"A Strezova","year":"2025","unstructured":"Strezova A, D\u00edez Domingo J, Cunningham AL, Eto T, Andrews C, Arns C, et al. Final analysis of the ZOE-LTFU trial to 11 years post-vaccination: efficacy of the adjuvanted recombinant zoster vaccine against herpes zoster and related complications. EClinicalMedicine. 2025;83:103241. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103241.","journal-title":"EClinicalMedicine"},{"key":"2754_CR60","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13070737","author":"A Wessely","year":"2025","unstructured":"Wessely A, Zwazl I, Poturica M, Weseslindtner L, Kundi M, Wiedermann U, et al. Antibody responses following primary immunization with the recombinant herpes zoster vaccine (Shingrix(\u00ae)) in VZV seronegative immunocompromised adults. Vaccines (Basel). 2025; https:\/\/doi.org\/10.3390\/vaccines13070737.","journal-title":"Vaccines (Basel)"},{"key":"2754_CR61","unstructured":"Robert Koch Institut. STIKO: Erweiterung der Herpes-zoster-Indikationsimpfempfehlung f\u00fcr Personen \u2265\u202f18\u00a0Jahre mit erh\u00f6htem Erkrankungsrisiko. Epid Bull. 2025;45."},{"key":"2754_CR62","unstructured":"European Medicines Agency. EPAR Penbraya. 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/penbraya. Zugegriffen: 14. Jan. 2026."},{"key":"2754_CR63","unstructured":"European Medicines Agency: EPAR Capavaxive. https:\/\/ec.europa.eu\/health\/documents\/community-register\/2026\/20260430169542\/anx_169542_de.pdf (2026). Accessed 24. Mai 2026."},{"issue":"1","key":"2754_CR64","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3\u201318. https:\/\/doi.org\/10.1136\/ard-2022-223356.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2754_CR65","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","volume":"83","author":"A Fanouriakis","year":"2024","unstructured":"Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024;83(1):15\u201329. https:\/\/doi.org\/10.1136\/ard-2023-224762.","journal-title":"Ann Rheum Dis"},{"issue":"9602","key":"2754_CR66","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60784-3","volume":"370","author":"JS Smolen","year":"2007","unstructured":"Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet. 2007;370(9602):1861\u201374. https:\/\/doi.org\/10.1016\/S0140-6736(07)60784-3.","journal-title":"Lancet"},{"issue":"6","key":"2754_CR67","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMc2107725","volume":"385","author":"D Mougiakakos","year":"2021","unstructured":"Mougiakakos D, Kr\u00f6nke G, V\u00f6lkl S, Kretschmann S, Aigner M, Kharboutli S, et al. CD19-targeted CAR T cells in refractory systemic Lupus erythematosus. N\u00a0Engl J Med. 2021;385(6):567\u20139. https:\/\/doi.org\/10.1056\/NEJMc2107725.","journal-title":"N Engl J Med"},{"key":"2754_CR68","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001235","author":"TR Riley","year":"2021","unstructured":"Riley TR, George MD. Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis. RMD Open. 2021; https:\/\/doi.org\/10.1136\/rmdopen-2020-001235.","journal-title":"RMD Open"},{"issue":"5","key":"2754_CR69","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1136\/ard.2010.128637","volume":"70","author":"K Au","year":"2011","unstructured":"Au K, Reed G, Curtis JR, Kremer JM, Greenberg JD, Strand V, et al. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(5):785\u201391. https:\/\/doi.org\/10.1136\/ard.2010.128637.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"2754_CR70","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.1016\/S2665-9913(19)30137-7","volume":"2","author":"A Pawar","year":"2020","unstructured":"Pawar A, Desai RJ, Gautam N, Kim SC. Risk of admission to hospital for serious infection after initiating tofacitinib versus biologic DMARDs in patients with rheumatoid arthritis: a multidatabase cohort study. The Lancet Rheumatology. 2020;2(2):e84\u2013e98. https:\/\/doi.org\/10.1016\/S2665-9913(19)30137-7.","journal-title":"The Lancet Rheumatology"},{"key":"2754_CR71","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1294416","volume":"14","author":"S Wu","year":"2023","unstructured":"Wu S, Xu Y, Yang L, Guo L, Jiang X. Short-term risk and long-term incidence rate of infection and malignancy with IL-17 and IL-23 inhibitors in adult patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Front Immunol. 2023;14:1294416. https:\/\/doi.org\/10.3389\/fimmu.2023.1294416.","journal-title":"Front Immunol"},{"issue":"10","key":"2754_CR72","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1136\/annrheumdis-2021-221244","volume":"80","author":"MA Friedman","year":"2021","unstructured":"Friedman MA, Curtis JR, Winthrop KL. Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases. Annals of the Rheumatic Diseases. 2021;80(10):1255\u201365. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221244.","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"6","key":"2754_CR73","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.anai.2023.01.010","volume":"130","author":"SS Mustafa","year":"2023","unstructured":"Mustafa SS. Steroid-induced secondary immune deficiency. Ann Allergy Asthma Immunol. 2023;130(6):713\u20137. https:\/\/doi.org\/10.1016\/j.anai.2023.01.010.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"2754_CR74","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8010015","volume":"8","author":"A Ibrahim","year":"2019","unstructured":"Ibrahim A, Ahmed M, Conway R, Carey JJ. Risk of infection with methotrexate therapy in inflammatory diseases: A systematic review and meta-analysis. J\u00a0Clin Med. 2019;8(1)15. https:\/\/doi.org\/10.3390\/jcm8010015.","journal-title":"J Clin Med"},{"issue":"8","key":"2754_CR75","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1080\/14760584.2020.1800462","volume":"19","author":"M Rivera-Izquierdo","year":"2020","unstructured":"Rivera-Izquierdo M, Valero-Ubierna MdC, Nieto-G\u00f3mez P, Mart\u00ednez-Bell\u00f3n MD, Fern\u00e1ndez-Mart\u00ednez NF, Barranco-Quintana JL. Vaccination in patients under monoclonal antibody treatment: an updated comprehensive review. Expert Rev Vaccines. 2020;19(8):727\u201344. https:\/\/doi.org\/10.1080\/14760584.2020.1800462.","journal-title":"Expert Rev Vaccines"},{"issue":"4","key":"2754_CR76","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N\u00a0Engl J Med. 2022;386(4):316\u201326. https:\/\/doi.org\/10.1056\/NEJMoa2109927.","journal-title":"N Engl J Med"},{"key":"2754_CR77","unstructured":"European Medicines Agency. Janus kinase inhibitors (JAKi) - referral. 2023. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/janus-kinase-inhibitors-jaki. Zugegriffen: 9. Febr. 2026."},{"issue":"11","key":"2754_CR78","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/j.ard.2025.05.014","volume":"84","author":"M Schaefer","year":"2025","unstructured":"Schaefer M, Purschke A, Zietemann V, Rudi T, Meissner Y, Richter A, et al. Comparative risk of incident malignancies in rheumatoid arthritis patients treated with Janus kinase inhibitors or bDMARDs: observational data from the German RABBIT register. Ann Rheum Dis. 2025;84(11):1779\u201390. https:\/\/doi.org\/10.1016\/j.ard.2025.05.014.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"2754_CR79","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1111\/1346-8138.17245","volume":"51","author":"Y Higashi","year":"2024","unstructured":"Higashi Y, Imafuku S, Tsuruta N, Murotani K, Group WJISDR. Systemic therapy for psoriasis and the risk of cutaneous infections. J\u00a0Dermatol. 2024;51(7):939\u201349. https:\/\/doi.org\/10.1111\/1346-8138.17245.","journal-title":"J Dermatol"},{"issue":"11","key":"2754_CR80","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1111\/jdv.12011","volume":"27","author":"AI S\u00e1nchez-Moya","year":"2013","unstructured":"S\u00e1nchez-Moya AI, Garc\u00eda-Doval I, Carretero G, S\u00e1nchez-Carazo J, Ferrandiz C, Herrera Ceballos E, et al. Latent tuberculosis infection and active tuberculosis in patients with psoriasis: a study on the incidence of tuberculosis and the prevalence of latent tuberculosis disease in patients with moderate\u2013severe psoriasis in Spain. BIOBADADERM registry. J\u00a0Eur Acad Dermatol Venereol. 2013;27(11):1366\u201374. https:\/\/doi.org\/10.1111\/jdv.12011.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2754_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2021.100266","volume":"13","author":"L Davidson","year":"2022","unstructured":"Davidson L, van den Reek J, Bruno M, van Hunsel F, Herings RMC, Matzaraki V, et al. Risk of candidiasis associated with interleukin-17 inhibitors: A real-world observational study of multiple independent sources. Lancet Reg Health Eur. 2022;13:100266. https:\/\/doi.org\/10.1016\/j.lanepe.2021.100266.","journal-title":"Lancet Reg Health Eur"},{"issue":"8","key":"2754_CR82","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1007\/s13555-024-01203-2","volume":"14","author":"M Mansilla-Polo","year":"2024","unstructured":"Mansilla-Polo M, Morgado-Carrasco D. Biologics versus JAK inhibitors. Part\u00a0II: Risk of infections. A\u00a0narrative review. Dermatol Ther (Heidelb). 2024;14(8):1983\u20132038. https:\/\/doi.org\/10.1007\/s13555-024-01203-2.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2754_CR83","unstructured":"Australian Government - Department of Health and Aged Care. Australian Immunisation Handbook. 2025. https:\/\/immunisationhandbook.health.gov.au\/contents\/vaccination-for-special-risk-groups\/vaccination-for-people-who-are-immunocompromised. Zugegriffen: 8. Okt. 2025."},{"issue":"Supplement_1","key":"2754_CR84","doi-asserted-by":"publisher","first-page":"S134","DOI":"10.1093\/clinids\/21.Supplement_1.S134","volume":"21","author":"CM Wilfert","year":"1995","unstructured":"Wilfert CM, Gross PA, Kaplan JE, Holmes KK, Masur H, Phair JP, et al. Quality standard for the enumeration of CD4+ lymphocytes in infants and children exposed to or infected with human immunodeficiency virus. Clin Infect Dis. 1995;21(Supplement_1):S134\u2013S5. https:\/\/doi.org\/10.1093\/clinids\/21.Supplement_1.S134.","journal-title":"Clin Infect Dis"},{"issue":"10380","key":"2754_CR85","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/s0140-6736(23)00273-8","volume":"401","author":"O Mitj\u00e0","year":"2023","unstructured":"Mitj\u00e0 O, Alemany A, Marks M, Lezama Mora JI, Rodr\u00edguez-Aldama JC, Torres Silva MS, et al. Mpox in people with advanced HIV infection: a global case series. Lancet. 2023;401(10380):939\u201349. https:\/\/doi.org\/10.1016\/s0140-6736(23)00273-8.","journal-title":"Lancet"},{"key":"2754_CR86","unstructured":"European AIDS Clinical Society. Immunisation in persons with HIV. 2025. https:\/\/eacs.sanfordguide.com\/en\/eacs-hiv\/eacs-section4\/vaccination. Zugegriffen: 18. Okt. 2025."},{"key":"2754_CR87","volume-title":"HIV 2026\/27","author":"C Hoffmann","year":"2025","unstructured":"Hoffmann C, Rockstroh J. HIV 2026\/27. Medizin Fokus Verlag; 2025."},{"issue":"Suppl 2","key":"2754_CR88","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1016\/j.cmi.2018.02.002","volume":"24","author":"KL Winthrop","year":"2018","unstructured":"Winthrop KL, Mariette X, Silva JT, Benamu E, Calabrese LH, Dumusc A, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clin Microbiol Infect. 2018;24(Suppl 2):S21\u2013S40. https:\/\/doi.org\/10.1016\/j.cmi.2018.02.002.","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"2754_CR89","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.jaad.2020.08.026","volume":"84","author":"S Akiyama","year":"2021","unstructured":"Akiyama S, Yamada A, Micic D, Sakuraba A. The risk of respiratory tract infections and interstitial lung disease with interleukin 12\/23 and interleukin 23 antagonists in patients with autoimmune diseases: A systematic review and meta-analysis. J\u00a0Am Acad Dermat. 2021;84(3):676\u201390. https:\/\/doi.org\/10.1016\/j.jaad.2020.08.026.","journal-title":"J Am Acad Dermat"},{"issue":"4","key":"2754_CR90","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1080\/14656566.2023.2178898","volume":"24","author":"L Dumitrescu","year":"2023","unstructured":"Dumitrescu L, Papathanasiou A, Coclitu C, Garjani A, Evangelou N, Constantinescu CS, et al. An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis. Expert Opin Pharmacother. 2023;24(4):495\u2013509. https:\/\/doi.org\/10.1080\/14656566.2023.2178898.","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"2754_CR91","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/s2468-1253(21)00377-0","volume":"7","author":"JS Lasa","year":"2022","unstructured":"Lasa JS, Olivera PA, Danese S, Peyrin-Biroulet L. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a\u00a0systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(2):161\u201370. https:\/\/doi.org\/10.1016\/s2468-1253(21)00377-0.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10306","key":"2754_CR92","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1016\/S0140-6736(21)00244-0","volume":"398","author":"MP McGinley","year":"2021","unstructured":"McGinley MP, Cohen JA. Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions. Lancet. 2021;398(10306):1184\u201394. https:\/\/doi.org\/10.1016\/S0140-6736(21)00244-0.","journal-title":"Lancet"},{"key":"2754_CR93","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/978-981-19-8421-1_16","volume-title":"Immune-mediated myopathies and neuropathies: Current trends and future prospects","author":"BL Gaspar","year":"2023","unstructured":"Gaspar BL. Classification of immune-mediated neuropathies. In: Immune-mediated myopathies and neuropathies: Current trends and future prospects. Singapore: Springer Nature Singapore; 2023. S. 207\u20138."},{"key":"2754_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.101452","volume":"37","author":"P Wildner","year":"2020","unstructured":"Wildner P, Stasio\u0142ek M, Matysiak M. Differential diagnosis of multiple sclerosis and other inflammatory CNS diseases. Mult Scler Relat Disord. 2020;37:101452. https:\/\/doi.org\/10.1016\/j.msard.2019.101452.","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"2754_CR95","doi-asserted-by":"publisher","DOI":"10.1212\/cpj.0000000000200462","volume":"15","author":"A Balshi","year":"2025","unstructured":"Balshi A, Leuenberger G, Dempsey J, Manning N, Baber U, Sloane JA. Herpes zoster infections with multiple sclerosis disease-modifying therapies: A\u00a0real-world pharmacovigilance study. Neurol Clin Pract. 2025;15(2)e200462. https:\/\/doi.org\/10.1212\/cpj.0000000000200462.","journal-title":"Neurol Clin Pract"},{"issue":"3","key":"2754_CR96","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jaci.2020.07.016","volume":"146","author":"HH Peter","year":"2020","unstructured":"Peter HH, Ochs HD, Cunningham-Rundles C, Vinh DC, Kiessling P, Greve B, et al. Targeting FcRn for immunomodulation: Benefits, risks, and practical considerations. J\u00a0Allergy Clin Immunol. 2020;146(3):479\u2013491.e5. https:\/\/doi.org\/10.1016\/j.jaci.2020.07.016.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"2754_CR97","doi-asserted-by":"publisher","first-page":"e195","DOI":"10.1016\/S1470-2045(25)00765-X","volume":"27","author":"SC Mellinghoff","year":"2026","unstructured":"Mellinghoff SC, Liss B, Stemler J, Petzer V, Egger-Heidrich K, Monin MB, et al. Anti-infective vaccination strategies in patients with haematological malignancies or solid tumours: updated guideline of the Infectious Diseases Working Party of the German Society for Hematology and Medical Oncology. The Lancet Oncology. 2026;27(4):e195\u2013e206. https:\/\/doi.org\/10.1016\/S1470-2045(25)00765-X.","journal-title":"The Lancet Oncology"},{"issue":"Suppl 2","key":"2754_CR98","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1016\/j.cmi.2018.02.009","volume":"24","author":"M Reinwald","year":"2018","unstructured":"Reinwald M, Silva JT, Mueller NJ, Fort\u00fan J, Garzoni C, de Fijter JW, ESCMID Study Group for Infections in Compromised Hosts (ESGICH), et al. Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors). Clin Microbiol Infect. 2018;24(Suppl 2):S53\u2013S70. https:\/\/doi.org\/10.1016\/j.cmi.2018.02.009.","journal-title":"Clin Microbiol Infect"},{"issue":"14","key":"2754_CR99","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1200\/jco.24.00032","volume":"42","author":"M Kamboj","year":"2024","unstructured":"Kamboj M, Bohlke K, Baptiste DM, Dunleavy K, Fueger A, Jones L, et al. Vaccination of adults with cancer: ASCO guideline. J\u00a0Clin Oncol. 2024;42(14):1699\u2013721. https:\/\/doi.org\/10.1200\/jco.24.00032.","journal-title":"J Clin Oncol"},{"issue":"10","key":"2754_CR100","doi-asserted-by":"publisher","first-page":"751","DOI":"10.46747\/cfp.6810751","volume":"68","author":"J Einarsson","year":"2022","unstructured":"Einarsson J, Wilkinson AN. Vaccination considerations for patients receiving cancer therapy. Can Fam Physician. 2022;68(10):751\u20132. https:\/\/doi.org\/10.46747\/cfp.6810751.","journal-title":"Can Fam Physician"},{"issue":"3","key":"2754_CR101","doi-asserted-by":"publisher","DOI":"10.1200\/edbk-25-473916","volume":"45","author":"MD Jain","year":"2025","unstructured":"Jain MD, Abramson JS, Ansell SM. Easy as ABC: Managing toxicities of antibody-drug conjugates, bispecific antibodies, and CAR T-cell therapies. Am Soc Clin Onco Ed Book. 2025;45(3)e473916. https:\/\/doi.org\/10.1200\/edbk-25-473916.","journal-title":"Am Soc Clin Onco Ed Book"},{"key":"2754_CR102","doi-asserted-by":"publisher","DOI":"10.1177\/2049936121989548","volume":"8","author":"I Ruiz-Camps","year":"2021","unstructured":"Ruiz-Camps I, Aguilar-Company J. Risk of infection associated with targeted therapies for solid organ and hematological malignancies. Ther Adv Infect Dis. 2021;8:2049936121989548. https:\/\/doi.org\/10.1177\/2049936121989548.","journal-title":"Ther Adv Infect Dis"},{"issue":"11","key":"2754_CR103","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1093\/infdis\/jiaa291","volume":"222","author":"CK Kang","year":"2020","unstructured":"Kang CK, Kim HR, Song KH, Keam B, Choi SJ, Choe PG, et al. Cell-mediated immunogenicity of influenza vaccination in patients with cancer receiving immune checkpoint inhibitors. J\u00a0Infect Dis. 2020;222(11):1902\u20139. https:\/\/doi.org\/10.1093\/infdis\/jiaa291.","journal-title":"J Infect Dis"},{"key":"2754_CR104","unstructured":"Naqvi A. Immunization in children with cancer. 2015. https:\/\/siop-online.org\/wp-content\/uploads\/2015\/11\/SIOP-PODC-Supportive-Care_Immunization-in-Children-with-Cancer_A-Naqvi.pdf. Zugegriffen: 11. Dez. 2025."},{"key":"2754_CR105","unstructured":"Rieger C, Liss B, Mellinghoff S, Buchheidt D, Cornely OA, Egerer G, et al. Onkopedia Leitlinie: Impfungen bei Tumorpatienten. 2019. https:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/impfungen-bei-tumorpatienten\/@@guideline\/html\/index.html. Zugegriffen: 15. Jan. 2026."},{"key":"2754_CR106","unstructured":"Maschmeyer G. Infektionen bei h\u00e4matologischen und onkologischen Patienten - \u00dcbersicht. 2024. https:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/infektionen-bei-haematologischen-und-onkologischen-patienten-uebersicht\/@@guideline\/html\/index.html. Zugegriffen: 15. Jan. 2026."},{"issue":"3","key":"2754_CR107","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/cid\/cit816","volume":"58","author":"LG Rubin","year":"2014","unstructured":"Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):309\u201318. https:\/\/doi.org\/10.1093\/cid\/cit816.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"2754_CR108","doi-asserted-by":"publisher","first-page":"e188","DOI":"10.1016\/s1473-3099(18)30601-7","volume":"19","author":"M Mikulska","year":"2019","unstructured":"Mikulska M, Cesaro S, de Lavallade H, Di Blasi R, Einarsdottir S, Gallo G, et al. Vaccination of patients with haematological malignancies who did not have transplantations: guidelines from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019;19(6):e188\u2013e99. https:\/\/doi.org\/10.1016\/s1473-3099(18)30601-7.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"2754_CR109","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/art.25033","volume":"62","author":"S van Assen","year":"2010","unstructured":"van Assen S, Holvast A, Benne CA, Posthumus MD, van Leeuwen MA, Voskuyl AE, et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum. 2010;62(1):75\u201381. https:\/\/doi.org\/10.1002\/art.25033.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"2754_CR110","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1182\/bloodadvances.2021006574","volume":"6","author":"C Pleyer","year":"2022","unstructured":"Pleyer C, Laing KJ, Ali MA, McClurkan CL, Soto S, Ahn IE, et al. BTK inhibitors impair humoral and cellular responses to recombinant zoster vaccine in CLL. Blood Adv. 2022;6(6):1732\u201340. https:\/\/doi.org\/10.1182\/bloodadvances.2021006574.","journal-title":"Blood Adv"},{"issue":"12","key":"2754_CR111","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","volume":"378","author":"JF Seymour","year":"2018","unstructured":"Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D\u2019Rozario J, Assouline S, et al. Venetoclax\u2013rituximab in relapsed or refractory chronic lymphocytic leukemia. N\u00a0Engl J Med. 2018;378(12):1107\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1713976.","journal-title":"N Engl J Med"},{"issue":"1","key":"2754_CR112","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41375-020-01016-0","volume":"35","author":"H Ludwig","year":"2021","unstructured":"Ludwig H, Boccadoro M, Moreau P, San-Miguel J, Cavo M, Pawlyn C, et al. Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. Leukemia. 2021;35(1):31\u201344. https:\/\/doi.org\/10.1038\/s41375-020-01016-0.","journal-title":"Leukemia"},{"issue":"3","key":"2754_CR113","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","volume":"128","author":"J Krejcik","year":"2016","unstructured":"Krejcik J, Casneuf T, Nijhof IS, Verbist B, Bald J, Plesner T, et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128(3):384\u201394. https:\/\/doi.org\/10.1182\/blood-2015-12-687749.","journal-title":"Blood"},{"issue":"Supplement 1","key":"2754_CR114","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1182\/blood-2025-408","volume":"146","author":"J Davis","year":"2025","unstructured":"Davis J, McElwee J, Julian K, Nachar V, Snyder J, Mahmoudjafari Z, et al. Safety of live-attenuated MMR vaccination in patients with multiple myeloma receiving daratumumab after autologous stem cell transplantation. Blood. 2025;146(Supplement 1):408. https:\/\/doi.org\/10.1182\/blood-2025-408.","journal-title":"Blood"},{"issue":"3","key":"2754_CR115","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/s1470-2045(09)70003-8","volume":"10","author":"P Fenaux","year":"2009","unstructured":"Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223\u201332. https:\/\/doi.org\/10.1016\/s1470-2045(09)70003-8.","journal-title":"Lancet Oncol"},{"issue":"12","key":"2754_CR116","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab504","volume":"8","author":"M Desjardins","year":"2021","unstructured":"Desjardins M, Mitre X, Sherman AC, Walsh SR, Cheng MP, Kanjilal S, et al. Safety of live-attenuated measles, mumps, and rubella vaccine administered within 2\u00a0years of hematopoietic cell transplant. Open Forum Infect Dis. 2021;8(12)ofab504. https:\/\/doi.org\/10.1093\/ofid\/ofab504.","journal-title":"Open Forum Infect Dis"},{"issue":"24","key":"2754_CR117","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17243892","volume":"17","author":"A Segura Tudela","year":"2025","unstructured":"Segura Tudela A, Geller R, Paiva B, Torres S\u00e1nchez SC, Gonz\u00e1lez Romero E, Lloret Madrid P, et al. The rise of fine-tuned CAR-based therapies against acute myeloid leukemia. Cancers. 2025;17(24)3892.","journal-title":"Cancers"},{"issue":"13","key":"2754_CR118","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1182\/bloodadvances.2024015346","volume":"9","author":"A Riedel","year":"2025","unstructured":"Riedel A, Phely L, Hug S, Faustmann P, Schroeder JC, Besemer B, et al. Immunological consequences of CAR T-cell therapy: an analysis of infectious complications and immune reconstitution. Blood Adv. 2025;9(13):3149\u201358. https:\/\/doi.org\/10.1182\/bloodadvances.2024015346.","journal-title":"Blood Adv"},{"issue":"1","key":"2754_CR119","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s41408-025-01321-w","volume":"15","author":"S Einarsdottir","year":"2025","unstructured":"Einarsdottir S, Lobaugh S, Luan D, Gomez-Llobell M, Subramanian P, Devlin S, et al. Humoral vaccine responses following Chimeric Antigen Receptor T-cell therapy for hematological malignancies. Blood Cancer\u00a0J. 2025;15(1):114\u2013114. https:\/\/doi.org\/10.1038\/s41408-025-01321-w.","journal-title":"Blood Cancer J"},{"key":"2754_CR120","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.146743","author":"CS Walti","year":"2021","unstructured":"Walti CS, Krantz EM, Maalouf J, Boonyaratanakornkit J, Keane-Candib J, Joncas-Schronce L, et al. Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies. JCI Insight. 2021; https:\/\/doi.org\/10.1172\/jci.insight.146743.","journal-title":"JCI Insight"},{"issue":"2","key":"2754_CR121","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s15010-020-01521-5","volume":"49","author":"I Los-Arcos","year":"2021","unstructured":"Los-Arcos I, Iacoboni G, Aguilar-Guisado M, Alsina-Manrique L, D\u00edaz de Heredia C, Fortuny-Guasch C, et al. Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a\u00a0position paper. Infection. 2021;49(2):215\u201331. https:\/\/doi.org\/10.1007\/s15010-020-01521-5.","journal-title":"Infection"},{"issue":"Suppl 1(Suppl 1","key":"2754_CR122","doi-asserted-by":"publisher","DOI":"10.1111\/tid.14109","volume":"25","author":"G Reynolds","year":"2023","unstructured":"Reynolds G, Hall VG, Teh BW. Vaccine schedule recommendations and updates for patients with hematologic malignancy post-hematopoietic cell transplant or CAR T-cell therapy. Transpl Infect Dis. 2023;25(Suppl 1(Suppl 1))e14109. https:\/\/doi.org\/10.1111\/tid.14109.","journal-title":"Transpl Infect Dis"},{"issue":"10","key":"2754_CR123","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.jtct.2024.07.018","volume":"30","author":"Z Shahid","year":"2024","unstructured":"Shahid Z, Jain T, Dioverti V, Pennisi M, Mikkilineni L, Thiruvengadam SK, et al. Best practice considerations by The American Society of Transplant and Cellular Therapy: Infection prevention and management after chimeric antigen receptor T cell therapy for hematological malignancies. Transplant Cell Ther. 2024;30(10):955\u201369. https:\/\/doi.org\/10.1016\/j.jtct.2024.07.018.","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"2754_CR124","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1080\/14760584.2025.2489659","volume":"24","author":"C Radcliffe","year":"2025","unstructured":"Radcliffe C, Kotton CN. Vaccination strategies for solid organ transplant candidates and recipients: insights and recommendations. Expert Rev Vaccines. 2025;24(1):313\u201323. https:\/\/doi.org\/10.1080\/14760584.2025.2489659.","journal-title":"Expert Rev Vaccines"},{"issue":"9","key":"2754_CR125","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13548","volume":"33","author":"M Malinis","year":"2019","unstructured":"Malinis M, Boucher HW, Practice obotAIDCo. Screening of donor and candidate prior to solid organ transplantation\u2014Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9)e13548. https:\/\/doi.org\/10.1111\/ctr.13548.","journal-title":"Clin Transplant"},{"issue":"7","key":"2754_CR126","doi-asserted-by":"publisher","DOI":"10.1111\/petr.13571","volume":"23","author":"S Suresh","year":"2019","unstructured":"Suresh S, Upton J, Green M, Pham-Huy A, Posfay-Barbe KM, Michaels MG, et al. Live vaccines after pediatric solid organ transplant: Proceedings of a consensus meeting, 2018. Pediatr Transplant. 2019;23(7)e13571. https:\/\/doi.org\/10.1111\/petr.13571.","journal-title":"Pediatr Transplant"},{"issue":"9","key":"2754_CR127","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13563","volume":"33","author":"L Danziger-Isakov","year":"2019","unstructured":"Danziger-Isakov L, Kumar D, The AST ID Community of Practice. Vaccination of solid organ transplant candidates and recipients: Guidelines from the American society of transplantation infectious diseases community of practice. Clinical Transplantation. 2019;33(9)e13563. https:\/\/doi.org\/10.1111\/ctr.13563.","journal-title":"Clinical Transplantation"},{"issue":"11","key":"2754_CR128","doi-asserted-by":"publisher","first-page":"1040.e11","DOI":"10.1016\/j.cmi.2015.07.014","volume":"21","author":"P P\u00e9rez-Romero","year":"2015","unstructured":"P\u00e9rez-Romero P, Bulnes-Ramos A, Torre-Cisneros J, Gavald\u00e1 J, Aydillo TA, Moreno A, et al. Influenza vaccination during the first 6 months after solid organ transplantation is efficacious and safe. Clin Microbiol Infect. 2015;21(11):1040.e11\u20131040.e18. https:\/\/doi.org\/10.1016\/j.cmi.2015.07.014.","journal-title":"Clin Microbiol Infect"},{"issue":"11","key":"2754_CR129","doi-asserted-by":"publisher","first-page":"e4090","DOI":"10.1093\/cid\/ciaa1097","volume":"73","author":"OS Kates","year":"2020","unstructured":"Kates OS, Haydel BM, Florman SS, Rana MM, Chaudhry ZS, Ramesh MS, et al. Coronavirus disease 2019 in solid organ transplant: A multicenter cohort study. Clin Infect Dis. 2020;73(11):e4090\u2013e9. https:\/\/doi.org\/10.1093\/cid\/ciaa1097.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"2754_CR130","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.cmi.2020.07.050","volume":"27","author":"H Testaert","year":"2021","unstructured":"Testaert H, Bouet M, Valour F, Gigandon A, Lafon ME, Philit F, et al. Incidence, management and outcome of respiratory syncytial virus infection in adult lung transplant recipients: a 9-year retrospective multicentre study. Clin Microbiol Infect. 2021;27(6):897\u2013903. https:\/\/doi.org\/10.1016\/j.cmi.2020.07.050.","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"2754_CR131","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13622","volume":"33","author":"SA Pergam","year":"2019","unstructured":"Pergam SA, Limaye AP. Varicella zoster virus in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9)e13622. https:\/\/doi.org\/10.1111\/ctr.13622.","journal-title":"Clin Transplant"},{"issue":"9","key":"2754_CR132","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13590","volume":"33","author":"PV Chin-Hong","year":"2019","unstructured":"Chin-Hong PV, Reid GE. Human papillomavirus infection in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9)e13590. https:\/\/doi.org\/10.1111\/ctr.13590.","journal-title":"Clin Transplant"},{"issue":"6","key":"2754_CR133","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1080\/23744235.2017.1285046","volume":"49","author":"LF Lundbo","year":"2017","unstructured":"Lundbo LF, Benfield T. Risk factors for community-acquired bacterial meningitis. Infect Dis (Lond). 2017;49(6):433\u201344. https:\/\/doi.org\/10.1080\/23744235.2017.1285046.","journal-title":"Infect Dis (Lond)"},{"issue":"1","key":"2754_CR134","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-022-00399-x","volume":"8","author":"MV Lenti","year":"2022","unstructured":"Lenti MV, Luu S, Carsetti R, Osier F, Ogwang R, Nnodu OE, et al. Asplenia and spleen hypofunction. Nat Rev Dis Primers. 2022;8(1)71. https:\/\/doi.org\/10.1038\/s41572-022-00399-x.","journal-title":"Nat Rev Dis Primers"},{"issue":"9785","key":"2754_CR135","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/S0140-6736(10)61493-6","volume":"378","author":"A Di Sabatino","year":"2011","unstructured":"Di Sabatino A, Carsetti R, Corazza GR. Post-splenectomy and hyposplenic states. The Lancet. 2011;378(9785):86\u201397. https:\/\/doi.org\/10.1016\/S0140-6736(10)61493-6.","journal-title":"The Lancet"},{"issue":"1","key":"2754_CR136","doi-asserted-by":"publisher","DOI":"10.70962\/jhi.20250003","volume":"1","author":"MC Poli","year":"2025","unstructured":"Poli MC, Aksentijevich I, Bousfiha AA, Cunningham-Rundles C, Hambleton S, Klein C, et al. Human inborn errors of immunity: 2024 update on the classification from the International Union of Immunological Societies Expert Committee. J\u00a0Hum Immun. 2025;1(1)e20250003. https:\/\/doi.org\/10.70962\/jhi.20250003.","journal-title":"J Hum Immun"},{"issue":"4","key":"2754_CR137","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1007\/s00103-019-02905-1","volume":"62","author":"N Wagner","year":"2019","unstructured":"Wagner N, Assmus F, Arendt G, Baum E, Baumann U, Bogdan C, et al. Impfen bei Immundefizienz: Anwendungshinweise zu den von der St\u00e4ndigen Impfkommission empfohlenen Impfungen. (IV) Impfen bei Autoimmunkrankheiten, bei anderen chronisch-entz\u00fcndlichen Erkrankungen und unter immunmodulatorischer Therapie. Bundesgesundheitsbl. 2019;62(4):494\u2013515. https:\/\/doi.org\/10.1007\/s00103-019-02905-1.","journal-title":"Bundesgesundheitsbl"},{"issue":"7","key":"2754_CR138","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1007\/s00431-021-03997-1","volume":"180","author":"LF Pittet","year":"2021","unstructured":"Pittet LF, Posfay-Barbe KM. Vaccination of immune compromised children\u2014an overview for physicians. Eur J Pediatr. 2021;180(7):2035\u201347. https:\/\/doi.org\/10.1007\/s00431-021-03997-1.","journal-title":"Eur J Pediatr"},{"issue":"13","key":"2754_CR139","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s15006-019-0715-1","volume":"161","author":"A Jablonka","year":"2019","unstructured":"Jablonka A, R\u00f6\u00dfler S, Pletz MW, Schleenvoigt BT. Impfen bei Immunschw\u00e4che: Das ist zu beachten. MMW - Fortschritte der Medizin. 2019;161(13):56\u201360. https:\/\/doi.org\/10.1007\/s15006-019-0715-1.","journal-title":"MMW - Fortschritte der Medizin"},{"issue":"1","key":"2754_CR140","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1136\/annrheumdis-2022-222574","volume":"82","author":"MHA Jansen","year":"2023","unstructured":"Jansen MHA, Rondaan C, Legger GE, Minden K, Uziel Y, Toplak N, et al. EULAR\/PRES recommendations for vaccination of paediatric patients with autoimmune inflammatory rheumatic diseases: update 2021. Ann Rheum Dis. 2023;82(1):35\u201347. https:\/\/doi.org\/10.1136\/annrheumdis-2022-222574.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"2754_CR141","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1158\/1078-0432.Ccr-14-2339","volume":"21","author":"L Liu","year":"2015","unstructured":"Liu L, Mayes PA, Eastman S, Shi H, Yadavilli S, Zhang T, et al. The BRAF and MEK inhibitors dabrafenib and trametinib: Effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4. Clin Cancer Res. 2015;21(7):1639\u201351. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-14-2339.","journal-title":"Clin Cancer Res"},{"key":"2754_CR142","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00035-19","author":"JS Davis","year":"2020","unstructured":"Davis JS, Ferreira D, Paige E, Gedye C, Boyle M. Infectious complications of biological and small molecule targeted immunomodulatory therapies. Clin Microbiol Rev. 2020; https:\/\/doi.org\/10.1128\/cmr.00035-19.","journal-title":"Clin Microbiol Rev"},{"issue":"10","key":"2754_CR143","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.37602","volume":"6","author":"AG Feldman","year":"2023","unstructured":"Feldman AG, Beaty BL, Ferrolino JA, Maron G, Weidner HK, Ali SA, et al. Safety and immunogenicity of live viral vaccines in a multicenter cohort of pediatric transplant recipients. JAMA Network Open. 2023;6(10)e2337602-e. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.37602.","journal-title":"JAMA Network Open"},{"issue":"11","key":"2754_CR144","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/j.ajt.2023.06.008","volume":"23","author":"PP Pich\u00e9-Renaud","year":"2023","unstructured":"Pich\u00e9-Renaud PP, Yue Lee E Y, Ji C, Qing Huang JY QH, Uleryk E, Teoh CW, et al. Safety and immunogenicity of the live-attenuated varicella vaccine in pediatric solid organ transplant recipients: A\u00a0systematic review and meta-analysis. Am J Transplant. 2023;23(11):1757\u201370. https:\/\/doi.org\/10.1016\/j.ajt.2023.06.008.","journal-title":"Am J Transplant"},{"issue":"11","key":"2754_CR145","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1111\/j.1600-6143.2012.04273.x","volume":"12","author":"KM Posfay-Barbe","year":"2012","unstructured":"Posfay-Barbe KM, Pittet LF, Sottas C, Grillet S, Wildhaber BE, Rodriguez M, et al. Varicella-zoster immunization in pediatric liver transplant recipients: safe and immunogenic. Am J Transplant. 2012;12(11):2974\u201385. https:\/\/doi.org\/10.1111\/j.1600-6143.2012.04273.x.","journal-title":"Am J Transplant"},{"issue":"3","key":"2754_CR146","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1111\/j.1600-6143.2005.01210.x","volume":"6","author":"A Weinberg","year":"2006","unstructured":"Weinberg A, Horslen SP, Kaufman SS, Jesser R, Devoll-Zabrocki A, Fleckten BL, et al. Safety and immunogenicity of varicella-zoster virus vaccine in pediatric liver and intestine transplant recipients. Am J Transplant. 2006;6(3):565\u20138. https:\/\/doi.org\/10.1111\/j.1600-6143.2005.01210.x.","journal-title":"Am J Transplant"},{"key":"2754_CR147","doi-asserted-by":"publisher","unstructured":"R\u00fcegg L, Pluma A, Hamroun S et\u00a0al. EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 update Annals of the Rheumatic Diseases, 2025; 84, 910\u2013926. https:\/\/doi.org\/10.1016\/j.ard.2025.02.023","DOI":"10.1016\/j.ard.2025.02.023"},{"key":"2754_CR148","unstructured":"Government of Alberta. Immunization recommendations for specific populations (immunosuppressed and chronic health conditions). 2025. https:\/\/open.alberta.ca\/dataset\/58d31634-61d9-469d-b95f-f714719b923e\/resource\/8a92b77b-351b-4f1e-9d4d-31aaa9effdb3\/download\/aip-specific-populations-immunocompromised.pdf. Zugegriffen: 8. Okt. 2025."},{"issue":"9","key":"2754_CR149","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/s2352-4642(23)00136-0","volume":"7","author":"T Fitzpatrick","year":"2023","unstructured":"Fitzpatrick T, Alsager K, Sadarangani M, Pham-Huy A, Murgu\u00eda-Favela L, Morris SK, et al. Immunological effects and safety of live rotavirus vaccination after antenatal exposure to immunomodulatory biologic agents: a prospective cohort study from the Canadian Immunization Research Network. Lancet Child Adolesc Health. 2023;7(9):648\u201356. https:\/\/doi.org\/10.1016\/s2352-4642(23)00136-0.","journal-title":"Lancet Child Adolesc Health"},{"issue":"2","key":"2754_CR150","doi-asserted-by":"publisher","first-page":"AB226","DOI":"10.1016\/j.jaci.2018.12.690","volume":"143","author":"A Penido","year":"2019","unstructured":"Penido\u00a0A, Paulo de Assis\u00a0J, Grecco\u00a0O, Barros\u00a0MT, Kalil\u00a0J, Kokron\u00a0CM, et\u00a0al. Vaccination against yellow fever in patients with IgA deficiency. J Allergy Clin Immunol. 2019;143(2):AB226. https:\/\/doi.org\/10.1016\/j.jaci.2018.12.690.","journal-title":"J Allergy Clin Immunol"},{"key":"2754_CR151","unstructured":"Centers for Disease Control and Prevention. Vaccines & immunizations: Altered immunocompetence. 2024. https:\/\/www.cdc.gov\/vaccines\/hcp\/imz-best-practices\/altered-immunocompetence.html. Zugegriffen: 17. Febr. 2026."},{"issue":"2","key":"2754_CR152","doi-asserted-by":"publisher","first-page":"245","DOI":"10.5858\/arpa.2018-0190-RS","volume":"144","author":"DR Matson","year":"2020","unstructured":"Matson DR, Yang DT. Autoimmune lymphoproliferative syndrome: An overview. Arch Pathol Lab Med. 2020;144(2):245\u201351. https:\/\/doi.org\/10.5858\/arpa.2018-0190-RS.","journal-title":"Arch Pathol Lab Med"},{"key":"2754_CR153","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.coi.2021.07.011","volume":"72","author":"V Oikonomou","year":"2021","unstructured":"Oikonomou V, Break TJ, Gaffen SL, Moutsopoulos NM, Lionakis MS. Infections in the monogenic autoimmune syndrome APECED. Curr Opin Immunol. 2021;72:286\u201397. https:\/\/doi.org\/10.1016\/j.coi.2021.07.011.","journal-title":"Curr Opin Immunol"},{"key":"2754_CR154","unstructured":"Platt CD. Immunizations in patients with inborn errors of immunity. 2026. https:\/\/www.uptodate.com\/contents\/immunizations-in-patients-with-inborn-errors-of-immunity. Zugegriffen: 11. Apr. 2026."},{"issue":"6","key":"2754_CR155","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.jaip.2016.09.012","volume":"4","author":"A Sobh","year":"2016","unstructured":"Sobh A, Bonilla FA. Vaccination in Primary Immunodeficiency Disorders. J\u00a0Allergy Clin Immunol Pract. 2016;4(6):1066\u201375. https:\/\/doi.org\/10.1016\/j.jaip.2016.09.012.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"9","key":"2754_CR156","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1136\/annrheumdis-2017-211128","volume":"76","author":"JK Park","year":"2017","unstructured":"Park JK, Lee MA, Lee EY, Song YW, Choi Y, Winthrop KL, et al. Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis. 2017;76(9):1559\u201365. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211128.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2754_CR157","doi-asserted-by":"publisher","DOI":"10.1111\/petr.14687","volume":"28","author":"A Keutler","year":"2024","unstructured":"Keutler A, Lainka E, Posovszky C. Live-attenuated vaccination for measles, mumps, and rubella in pediatric liver transplantation. Pediatr Transplant. 2024;28(1)e14687. https:\/\/doi.org\/10.1111\/petr.14687.","journal-title":"Pediatr Transplant"},{"issue":"2","key":"2754_CR158","first-page":"272","volume":"34","author":"JL Kaine","year":"2007","unstructured":"Kaine JL, Kivitz AJ, Birbara C, Luo AY. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J\u00a0Rheumatol. 2007;34(2):272\u20139.","journal-title":"J Rheumatol"},{"issue":"4","key":"2754_CR159","doi-asserted-by":"publisher","first-page":"648","DOI":"10.3899\/jrheum.130945","volume":"41","author":"AJ Kivitz","year":"2014","unstructured":"Kivitz AJ, Schechtman J, Texter M, Fichtner A, de Longueville M, Chartash EK. Vaccine responses in patients with rheumatoid arthritis treated with certolizumab pegol: results from a single-blind randomized phase IV trial. J\u00a0Rheumatol. 2014;41(4):648\u201357. https:\/\/doi.org\/10.3899\/jrheum.130945.","journal-title":"J Rheumatol"},{"issue":"3","key":"2754_CR160","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.anai.2024.05.014","volume":"133","author":"JA Lieberman","year":"2024","unstructured":"Lieberman JA, Chu DK, Ahmed T, Dribin TE, Abrams EM, Anagnostou A, et al. A systematic review and expert Delphi Consensus recommendation on the use of vaccines in patients receiving dupilumab: A position paper of the American College of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol. 2024;133(3):286\u201394. https:\/\/doi.org\/10.1016\/j.anai.2024.05.014.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"2754_CR161","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jaad.2021.03.032","volume":"85","author":"JF Merola","year":"2021","unstructured":"Merola JF, Bagel J, Almgren P, R\u00f8pke MA, Lophaven KW, Vest NS, et al. Tralokinumab does not impact vaccine-induced immune responses: Results from a 30-week, randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis. J\u00a0Am Acad Dermatol. 2021;85(1):71\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2021.03.032.","journal-title":"J Am Acad Dermatol"},{"key":"2754_CR162","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/9355606","volume":"2022","author":"DR Dorscheid","year":"2022","unstructured":"Dorscheid DR, Lee JK, Ramesh W, Greenwald M, Del Carpio J. Guidance for administering biologics for severe asthma and allergic conditions. Can Respir\u00a0J. 2022;2022:9355606. https:\/\/doi.org\/10.1155\/2022\/9355606.","journal-title":"Can Respir J"},{"issue":"9","key":"2754_CR163","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000209888","volume":"103","author":"M Ringelstein","year":"2024","unstructured":"Ringelstein M, Asseyer S, Lindenblatt G, Fischer K, Pul R, Skuljec J, et al. Eculizumab use in neuromyelitis optica spectrum disorders: Routine clinical care data from a European cohort. Neurology. 2024;103(9)e209888. https:\/\/doi.org\/10.1212\/wnl.0000000000209888.","journal-title":"Neurology"},{"key":"2754_CR164","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00628","volume":"11","author":"C Bettoni da Cunha-Riehm","year":"2020","unstructured":"Bettoni da Cunha-Riehm C, Hildebrand V, Nathrath M, Metzler M, Suttorp M. Vaccination with live attenuated vaccines in four children with chronic myeloid leukemia while on imatinib treatment. Front Immunol. 2020;11:00628. https:\/\/doi.org\/10.3389\/fimmu.2020.00628.","journal-title":"Front Immunol"},{"issue":"1","key":"2754_CR165","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01469-6","volume":"8","author":"S Shyam Sunder","year":"2023","unstructured":"Shyam Sunder S, Sharma UC, Pokharel S. Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management. Signal Transduct Target Ther. 2023;8(1)262. https:\/\/doi.org\/10.1038\/s41392-023-01469-6.","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"2754_CR166","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1182\/bloodadvances.2025018225","volume":"10","author":"R Banerjee","year":"2026","unstructured":"Banerjee R, Raje NS. Vaccination during bispecific antibody treatment for myeloma. Blood Advances. 2026;10(2):519\u201320.","journal-title":"Blood Advances"},{"key":"2754_CR167","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2026.105253","volume":"221","author":"A Lasagna","year":"2026","unstructured":"Lasagna A, Del Re M, Danesi R, Andreoni M, Tessitore D, Di Maio M, et al. Bispecific antibodies in solid tumors: An Italian Association of Medical Oncology (AIOM) multidisciplinary perspective on immunology and vaccination. Critical Reviews in Oncology\/Hematology. 2026;221:105253. https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105253.","journal-title":"Critical Reviews in Oncology\/Hematology"},{"issue":"1","key":"2754_CR168","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41408-024-01139-y","volume":"14","author":"AJ Devasia","year":"2024","unstructured":"Devasia AJ, Chari A, Lancman G. Bispecific antibodies in the treatment of multiple myeloma. Blood Cancer\u00a0J. 2024;14(1):158\u2013158. https:\/\/doi.org\/10.1038\/s41408-024-01139-y.","journal-title":"Blood Cancer J"},{"issue":"7","key":"2754_CR169","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1182\/bloodadvances.2025018688","volume":"10","author":"SK Chiu","year":"2026","unstructured":"Chiu SK, Furlong E, Fox A, McKinnon EJ, Ovando SS, McLean-Tooke A, et al. Blinatumomab limits humoral antibody response despite boosting the influenza vaccine schedule in children with B-ALL. Blood Advances. 2026;10(7):2425\u20138. https:\/\/doi.org\/10.1182\/bloodadvances.2025018688.","journal-title":"Blood Advances"},{"issue":"1","key":"2754_CR170","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1182\/bloodadvances.2023011658","volume":"8","author":"KA Frerichs","year":"2023","unstructured":"Frerichs KA, Verkleij CPM, Mateos MV, Martin TG, Rodriguez C, Nooka A, et al. Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation. Blood Advances. 2023;8(1):194\u2013206. https:\/\/doi.org\/10.1182\/bloodadvances.2023011658.","journal-title":"Blood Advances"},{"issue":"22","key":"2754_CR171","doi-asserted-by":"publisher","first-page":"5752","DOI":"10.1182\/bloodadvances.2025016613","volume":"9","author":"C Schinke","year":"2025","unstructured":"Schinke C, Rodriguez-Otero P, van de Donk NWCJ, Lipe B, Lavi N, Rasche L, et al. Infections and parameters of humoral immunity with talquetamab in relapsed\/refractory multiple myeloma in MonumenTAL-1. Blood Advances. 2025;9(22):5752\u201362. https:\/\/doi.org\/10.1182\/bloodadvances.2025016613.","journal-title":"Blood Advances"},{"issue":"4","key":"2754_CR172","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.6345","volume":"7","author":"R Carvajal","year":"2024","unstructured":"Carvajal R, Zabalza A, Carbonell-Mirabent P, Mart\u00ednez-G\u00f3mez X, Esperalba J, Pappolla A, et al. Vaccine safety and immunogenicity in patients with multiple sclerosis treated with natalizumab. JAMA Netw Open. 2024;7(4)e246345. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.6345.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"2754_CR173","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41582-022-00646-5","volume":"18","author":"A Winkelmann","year":"2022","unstructured":"Winkelmann A, Loebermann M, Barnett M, Hartung HP, Zettl UK. Vaccination and immunotherapies in neuroimmunological diseases. Nat Rev Neurol. 2022;18(5):289\u2013306. https:\/\/doi.org\/10.1038\/s41582-022-00646-5.","journal-title":"Nat Rev Neurol"},{"key":"2754_CR174","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104793","volume":"77","author":"S Paybast","year":"2023","unstructured":"Paybast S, Sahraian MA, Nahayati MA, Habibi MA, Shahmohammadi S, Navardi S. Investigation of the safety of live attenuated varicella-zoster virus vaccination in patients with relapse-remitting multiple sclerosis treated with natalizumab: A case series and review of the literature. Mult Scler Relat Disord. 2023;77:104793. https:\/\/doi.org\/10.1016\/j.msard.2023.104793.","journal-title":"Mult Scler Relat Disord"},{"issue":"8","key":"2754_CR175","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1177\/13524585231168043","volume":"29","author":"S Otero-Romero","year":"2023","unstructured":"Otero-Romero S, Lebrun-Fr\u00e9nay C, Reyes S, Amato MP, Campins M, Farez M, et al. ECTRIMS\/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs. Mult Scler. 2023;29(8):904\u201325. https:\/\/doi.org\/10.1177\/13524585231168043.","journal-title":"Mult Scler"},{"issue":"1","key":"2754_CR176","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000000409","volume":"5","author":"C von Hehn","year":"2018","unstructured":"von Hehn C, Howard J, Liu S, Meka V, Pultz J, Mehta D, et al. Immune response to vaccines is maintained in patients treated with dimethyl fumarate. Neurol Neuroimmunol Neuroinflamm. 2018;5(1)e409. https:\/\/doi.org\/10.1212\/nxi.0000000000000409.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"7","key":"2754_CR177","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/s41409-018-0112-x","volume":"53","author":"A Pandit","year":"2018","unstructured":"Pandit A, Leblebjian H, Hammond SP, Laubach JP, Richardson PG, Baden LR, et al. Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation. Bone Marrow Transplant. 2018;53(7):942\u20135. https:\/\/doi.org\/10.1038\/s41409-018-0112-x.","journal-title":"Bone Marrow Transplant"},{"key":"2754_CR178","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12121449","author":"A Silva-Pinto","year":"2024","unstructured":"Silva-Pinto A, Abreu I, Martins A, Bastos J, Ara\u00fajo J, Pinto R. Vaccination after haematopoietic stem cell transplant: A review of the literature and proposed vaccination protocol. Vaccines (Basel). 2024; https:\/\/doi.org\/10.3390\/vaccines12121449.","journal-title":"Vaccines (Basel)"},{"issue":"9","key":"2754_CR179","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.33828","volume":"8","author":"R Redjoul","year":"2025","unstructured":"Redjoul R, Robin C, Softic L, Ourghanlian C, Cabanne L, Beckerich F, et al. Respiratory syncytial virus vaccination in allogeneic hematopoietic stem cell transplant recipients. JAMA Netw Open. 2025;8(9)e2533828. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.33828.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"2754_CR180","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70062","volume":"9","author":"S Stock","year":"2025","unstructured":"Stock S, B\u00fccklein VL, Blumenberg V, Magno G, Emhardt AJ, Holzem AME, et al. Prognostic significance of immune reconstitution following CD19 CAR T-cell therapy for relapsed\/refractory B-cell lymphoma. HemaSphere. 2025;9(1)e70062. https:\/\/doi.org\/10.1002\/hem3.70062.","journal-title":"HemaSphere"},{"key":"2754_CR181","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11101611","author":"M Vigan\u00f2","year":"2023","unstructured":"Vigan\u00f2 M, Beretta M, Lepore M, Abete R, Benatti SV, Grassini MV, et al. Vaccination recommendations in solid organ transplant adult candidates and recipients. Vaccines (Basel). 2023; https:\/\/doi.org\/10.3390\/vaccines11101611.","journal-title":"Vaccines (Basel)"},{"issue":"3","key":"2754_CR182","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1093\/cid\/cit684","volume":"58","author":"LG Rubin","year":"2014","unstructured":"Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):e44\u2013e100. https:\/\/doi.org\/10.1093\/cid\/cit684.","journal-title":"Clin Infect Dis"},{"key":"2754_CR183","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/tay018","author":"V Hall","year":"2018","unstructured":"Hall V, Johnson D, Torresi J. Travel and biologic therapy: travel-related infection risk, vaccine response and recommendations. J\u00a0Travel Med. 2018; https:\/\/doi.org\/10.1093\/jtm\/tay018.","journal-title":"J Travel Med"},{"issue":"Rr-7","key":"2754_CR184","first-page":"1","volume":"59","author":"JE Staples","year":"2010","unstructured":"Staples JE, Gershman M, Fischer M. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010;59(Rr-7):1\u201327.","journal-title":"MMWR Recomm Rep"},{"key":"2754_CR185","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.tmaid.2017.12.004","volume":"21","author":"A Rosdahl","year":"2018","unstructured":"Rosdahl A, Herzog C, Fr\u00f6sner G, Nor\u00e9n T, Rombo L, Askling HH. An extra priming dose of hepatitis\u00a0A vaccine to adult patients with rheumatoid arthritis and drug induced immunosuppression - A prospective, open-label, multi-center study. Travel Med Infect Dis. 2018;21:43\u201350. https:\/\/doi.org\/10.1016\/j.tmaid.2017.12.004.","journal-title":"Travel Med Infect Dis"},{"issue":"3","key":"2754_CR186","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1093\/infdis\/jiv060","volume":"212","author":"HM Garcia Garrido","year":"2015","unstructured":"Garcia Garrido HM, Wieten RW, Grobusch MP, Goorhuis A. Response to Hepatitis A Vaccination in Immunocompromised Travelers. J\u00a0Infect Dis. 2015;212(3):378\u201385. https:\/\/doi.org\/10.1093\/infdis\/jiv060.","journal-title":"J Infect Dis"},{"key":"2754_CR187","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/taae125","author":"JL Schnyder","year":"2025","unstructured":"Schnyder JL, Garcia Garrido HM, Tanck MW, Maurer I, Harskamp AM, Kootstra N, et al. Hepatitis a vaccine immunogenicity and boostability in adults receiving immunosuppressive therapy and adults living with HIV: a prospective single-centre cohort study. J\u00a0Travel Med. 2025; https:\/\/doi.org\/10.1093\/jtm\/taae125.","journal-title":"J Travel Med"},{"issue":"5","key":"2754_CR188","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1007\/s00103-020-03123-w","volume":"63","author":"HJ Laws","year":"2020","unstructured":"Laws HJ, Baumann U, Bogdan C, Burchard G, Christopeit M, Hecht J, et al. Impfen bei Immundefizienz. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz. 2020;63(5):588\u2013644. https:\/\/doi.org\/10.1007\/s00103-020-03123-w.","journal-title":"Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz"},{"key":"2754_CR189","unstructured":"World Health Organization. Countries with risk of yellow fever transmission and countries requiring yellow fever vaccination (November 2022). 2022. https:\/\/www.who.int\/publications\/m\/item\/countries-with-risk-of-yellow-fever-transmission-and-countries-requiring-yellow-fever-vaccination-(november-2022). Zugegriffen: 19. Febr. 2026."},{"key":"2754_CR190","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000000726","author":"A Huttner","year":"2020","unstructured":"Huttner A, Eperon G, Lascano AM, Roth S, Schwob JM, Siegrist CA, et al. Risk of MS relapse after yellow fever vaccination: A self-controlled case series. Neurol Neuroimmunol Neuroinflamm. 2020; https:\/\/doi.org\/10.1212\/nxi.0000000000000726.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"23","key":"2754_CR191","doi-asserted-by":"publisher","first-page":"5985","DOI":"10.3390\/ijms20235985","volume":"20","author":"L Rolfes","year":"2019","unstructured":"Rolfes L, Pawlitzki M, Pfeuffer S, Thomas C, Schmidt-Chanasit J, Gross CC, et al. Fulminant MS reactivation following combined fingolimod cessation and yellow fever vaccination. Int J Molec Sci. 2019;20(23):5985\u20135985. https:\/\/doi.org\/10.3390\/ijms20235985.","journal-title":"Int J Molec Sci"},{"key":"2754_CR192","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/taaa126","author":"S B\u00fchler","year":"2020","unstructured":"B\u00fchler S, Jaeger VK, Eperon G, Furrer H, Fux CA, Jansen S, et al. Safety and immunogenicity of a primary yellow fever vaccination under low-dose methotrexate therapy-a prospective multi-centre pilot study 1. J\u00a0Travel Med. 2020; https:\/\/doi.org\/10.1093\/jtm\/taaa126.","journal-title":"J Travel Med"},{"issue":"8","key":"2754_CR193","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/s1473-3099(23)00114-7","volume":"23","author":"D Kimathi","year":"2023","unstructured":"Kimathi D, Juan-Giner A, Orindi B, Grantz KH, Bob NS, Cheruiyot S, et al. Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial. Lancet Infect Dis. 2023;23(8):974\u201382. https:\/\/doi.org\/10.1016\/s1473-3099(23)00114-7.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"2754_CR194","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjid.2024.103719","volume":"28","author":"E Motta","year":"2024","unstructured":"Motta E, Camacho LAB, Filippis AMB, Costa M, Pedro L, Cardoso SW, et al. Safety of the yellow fever vaccine in people living with HIV: a longitudinal study exploring post-vaccination viremia and hematological and liver kinetics. Braz J Infect Dis. 2024;28(1)103719. https:\/\/doi.org\/10.1016\/j.bjid.2024.103719.","journal-title":"Braz J Infect Dis"},{"key":"2754_CR195","unstructured":"European Centre for Disease Prevention and Control. Communicable disease threats report, 27 September - 3\u00a0October 2025, week\u00a040. 2025. https:\/\/www.ecdc.europa.eu\/en\/publications-data\/communicable-disease-threats-report-27-september-3-october-2025-week-40. Zugegriffen: 12. Dez. 2025."},{"key":"2754_CR196","unstructured":"Robert Koch Institut. Tollwut: RKI-Ratgeber. 2025. https:\/\/www.rki.de\/DE\/Aktuelles\/Publikationen\/RKI-Ratgeber\/Ratgeber\/Ratgeber_Tollwut.html. Zugegriffen: 12. Dez. 2025."},{"issue":"33","key":"2754_CR197","doi-asserted-by":"publisher","first-page":"5091","DOI":"10.1016\/j.vaccine.2020.06.037","volume":"38","author":"P Parize","year":"2020","unstructured":"Parize P, Poujol P, Morineau Le Houssine P, Goesch J, Lucet C, Basuyau L, et al. Immune response to rabies post-exposure prophylaxis in patients with non-HIV secondary immunodeficiencies. Vaccine. 2020;38(33):5091\u20134. https:\/\/doi.org\/10.1016\/j.vaccine.2020.06.037.","journal-title":"Vaccine"},{"key":"2754_CR198","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/taac148","author":"HM Garcia Garrido","year":"2022","unstructured":"Garcia Garrido HM, van Put B, Terryn S, de Pijper CA, Stijnis C, D\u2019Haens GR, et al. Immunogenicity and 1-year boostability of a three-dose intramuscular rabies pre-exposure prophylaxis schedule in adults receiving immunosuppressive monotherapy: a prospective single-centre clinical trial. J\u00a0Travel Med. 2022; https:\/\/doi.org\/10.1093\/jtm\/taac148.","journal-title":"J Travel Med"},{"issue":"26","key":"2754_CR199","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.126407","volume":"42","author":"J Percio","year":"2024","unstructured":"Percio J, Kobayashi CD, Silva RMA, Marinho A, Capovilla L, Andrade PHS, et al. Safety signal detected: Anaphylaxis after attenuated dengue vaccine (TAK-003) - Brazil, march 1, 2023-march 11, 2024. Vaccine. 2024;42(26)126407. https:\/\/doi.org\/10.1016\/j.vaccine.2024.126407.","journal-title":"Vaccine"},{"key":"2754_CR200","unstructured":"Robert Koch Institut. Empfehlungen der St\u00e4ndigen Impfkommission (STIKO) und der Deutschen Gesellschaft f\u00fcr Tropenmedizin, Reisemedizin und Globale Gesundheit e.\u202fV. (DTG) zu Reiseimpfungen. Epid Bull. 2025;14."},{"key":"2754_CR201","unstructured":"European Centre for Disease Prevention and Control. Chikungunya virus disease worldwide overview. 2025. https:\/\/www.ecdc.europa.eu\/en\/chikungunya-monthly. Zugegriffen: 12. Dez. 2025."},{"key":"2754_CR202","unstructured":"European Medicines Agency: EPAR Imvanex. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/variation\/imvanex (2026). Zugegriffen: 30. Jun. 2026."},{"issue":"12","key":"2754_CR203","doi-asserted-by":"publisher","first-page":"e349","DOI":"10.1016\/s1473-3099(22)00574-6","volume":"22","author":"GA Poland","year":"2022","unstructured":"Poland GA, Kennedy RB, Tosh PK. Prevention of monkeypox with vaccines: a rapid review. Lancet Infect Dis. 2022;22(12):e349\u2013e58. https:\/\/doi.org\/10.1016\/s1473-3099(22)00574-6.","journal-title":"Lancet Infect Dis"},{"key":"2754_CR204","unstructured":"Robert Koch Institut. Mpox: RKI-Ratgeber. 2025. https:\/\/www.rki.de\/DE\/Aktuelles\/Publikationen\/RKI-Ratgeber\/Ratgeber\/Ratgeber_Mpox.html. Zugegriffen: 12. Dez. 2025."},{"key":"2754_CR205","unstructured":"Paul-Ehrlich-Institut. Ebola vaccines. 2026. https:\/\/www.pei.de\/EN\/medicinal-products\/vaccines-human\/ebola\/ebola-node.html. Zugegriffen: 2. M\u00e4rz 2026."},{"key":"2754_CR206","unstructured":"European Medicines Agency: EPAR Mvabea. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mvabea (2026). Zugegriffen: 24. Mai 2026."},{"key":"2754_CR207","unstructured":"European Medicines Agency: EPAR Zabdeno. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zabdeno (2026). Zugegriffen: 24. Mai 2026."},{"key":"2754_CR208","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12050497","author":"JA Ake","year":"2024","unstructured":"Ake JA, Paolino K, Hutter JN, Cicatelli SB, Eller LA, Eller MA, et al. Safety and immunogenicity of an accelerated Ebola vaccination schedule in people with and without human immunodeficiency virus: A randomized clinical trial. Vaccines (Basel). 2024; https:\/\/doi.org\/10.3390\/vaccines12050497.","journal-title":"Vaccines (Basel)"},{"issue":"4","key":"2754_CR209","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1093\/cid\/ciae215","volume":"79","author":"B Mwesigwa","year":"2024","unstructured":"Mwesigwa B, Sawe F, Oyieko J, Mwakisisile J, Viegas E, Akintunde GA, et al. Safety and immunogenicity of accelerated heterologous 2-dose Ebola vaccine regimens in adults with and without HIV in Africa. Clin Infect Dis. 2024;79(4):888\u2013900. https:\/\/doi.org\/10.1093\/cid\/ciae215.","journal-title":"Clin Infect Dis"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-026-02754-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-026-02754-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-026-02754-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:14:26Z","timestamp":1785518066000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-026-02754-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":209,"journal-issue":{"issue":"S8","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["2754"],"URL":"https:\/\/doi.org\/10.1007\/s00508-026-02754-4","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"14 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"U.\u00a0Wiedermann war Principal Investigator firmengesponserter klinischer Studien (durch GlaxoSmithKline, Novartis, Merck Sharp & Dohme) an der Medizinischen Universit\u00e4t Wien ohne pers\u00f6nliche Honorare. A.\u00a0Wagner erhielt Honorare f\u00fcr Vortr\u00e4ge (GlaxoSmithKline, Merck Sharp & Dohme, Pfizer, Valneva), Reise- und Kongressunterst\u00fctzung (AstraZeneca, Merck Sharp & Dohme) und war Principal Investigator einer unterst\u00fctzten kollaborativen klinischen Studie (GlaxoSmithKline). A.\u00a0Bartuschka erhielt Vortragshonorare von Abbvie, Almirall, Amgen, Astropharma, GlaxoSmithKline und Janssen. A.S.\u00a0Berghoff erhielt Forschungsf\u00f6rderung von Daiichi Sankyo und Roche sowie Honorare f\u00fcr Vortr\u00e4ge, Beratungen oder die Teilnahme an Advisory Boards von Roche, Bristol-Myers Squibb, Merck, Daiichi Sankyo, AstraZeneca, CeCaVa, Seagen, Alexion, Servier, Pfizer und Ygion. Dar\u00fcber hinaus erhielt sie Reisekostenunterst\u00fctzung von Roche, Gilead, Amgen und AbbVie. A.\u00a0Eser hat keine Interessenkonflikte in Bezug auf den Themenkreis Impfungen. Er erhielt Vortragshonorare von Abbvie, Janssen, Johnson & Johnson, Takeda, Galapagos, Astropharma und Eli Lilly sowie Forschungsf\u00f6rderung von Abbvie, Takeda, den Wissenschaftsfonds des B\u00fcrgermeisters der Stadt Wien. Er war Principal Investigator firmengesponserter klinischer Studien (durch Centocor\/Johnson & Johnson und Takeda). E.\u00a0F\u00f6rster-Waldl erhielt Projektsponsoring durch Pharming. L.\u00a0G\u00f6schl erhielt pers\u00f6nliche Honorare von Johnson & Johnson, Alfasigma und Takeda. K.\u00a0Grabmeier-Pfistershammer gibt an, keine Interessenkonflikte bez\u00fcglich der Thematik Impfungen zu haben. Sie war Principal Investigator firmengesponsorter klinischer Studien (durch GlaxoSmithKline, Novartis, Merck Sharp & Dohme) an der Medizinischen Universit\u00e4t Wien ohne pers\u00f6nliche Honorare und erhielt Honorare f\u00fcr Beratungen und Reiseunterst\u00fctzung von Merck Sharp & Dohme, Gilead Sciences und GlaxoSmithKline. F.\u00a0Keil erhielt Zusch\u00fcsse und Forschungsf\u00f6rderung von Johnson & Johnson, AbbVie, Mundipharma, BeiGene und Bristol-Myers Squibb sowie Honorare oder Beratungsgeb\u00fchren von Novartis, Incyte, Takeda, Roche, AbbVie, Bristol-Myers Squibb und Johnson & Johnson. Er ist Investigator einer firmengesponserten klinischen Studie von Bristol-Myers Squibb. S.\u00a0Koppelst\u00e4tter erhielt Vortragshonorare von GlaxoSmithKline, Merck Sharp & Dohme und Shionogi. B.\u00a0Kornek erhielt Vortragshonorare und Honorare f\u00fcr Beratung von Biogen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Merck, Neuraxpharm, Novartis, Roche, Sanofi, Teva, Takeda. Sie war Principal Investigator Phase-III-gesponserter Studien von Novartis und Roche ohne pers\u00f6nliche Honorare an der Medizinischen Universit\u00e4t Wien. R.\u00a0Krause erhielt Forschungsf\u00f6rderung f\u00fcr investigatorinitiierte Studien von Merck, Pfizer und Mundipharma, ohne Bezug zur vorliegenden Arbeit. W.F.\u00a0Pickl erhielt Honorare f\u00fcr Vortr\u00e4ge (Novartis, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline) und f\u00fcr die Teilnahme an Advisory Boards (Novartis, Merck Sharp & Dohme). C.\u00a0Scheinecker war Principal Investigator firmengesponsorter klinischer Studien an der Medizinischen Universit\u00e4t Wien ohne pers\u00f6nliche Honorare; er erhielt Vortragshonorare (AbbVie, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Janssen, Eli Lilly, Merck Sharp & Dohme, Novartis, Otsuka, Pfizer, Roche, UCB), Konsulentenhonorare (Novartis) und Autorenhonorare (Fakten der Rheumatologie). B.\u00a0Waas erhielt ein Honorar f\u00fcr Vortr\u00e4ge (Pfizer) und ein Honorar f\u00fcr die Teilnahme an einem Expert:innen-Symposium (GlaxoSmithKline). G.\u00a0Weiss erhielt Honorare f\u00fcr Vortr\u00e4ge von Astropharma, Fresenius-Kabi, Menarini, Merck Sharp & Dohme, Pfizer, Sandoz, Shionogi und Vifor sowie f\u00fcr die Teilnahme an Advisory Boards von AOP Orphan, Aurovir und Cajal Neuroscience. A.\u00a0Donschacher, E.\u00a0K\u00f6nig und L.\u00a0Wisgrill geben an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}